Lämmle B, Griffin J H
Clin Haematol. 1985 Jun;14(2):281-342.
Let us now briefly summarize some major known regulating mechanisms, most of which have already been discussed. A general regulating feature of the coagulation system is provided by the cofactors HMW-kininogen, tissue factor, factor V(a), factor VIII:C(a), protein S and thrombomodulin. Tissue factor and thrombomodulin, as cell membrane constituents, and the other cofactors, thanks to their affinity for certain surface sites, localize coagulation reactions and thus avoid generalized intravascular thrombosis when the clotting system is triggered. Thrombin activates factors V and VIII:C and activated protein C inactivates factors Va and VIII:Ca. Thrombin is regulated by AT III, alpha 2M and possibly heparin-cofactor II, whereby endothelial-cell-bound heparin-like molecules enhance thrombin neutralization. Moreover, binding of thrombin to thrombomodulin abolishes its clotting activity, at least in the case of rabbit thrombomodulin. Thrombin is able to cleave PT-fragment 1 from prothrombin, thus generating prethrombin 1, which lacks the gla-region and does not bind to phospholipids. The hypothesis that thrombin may regulate its own formation by this negative feedback, however, must probably be discarded, because no corresponding fragments are found after blood clotting in vitro (Aronson et al, 1977). Factor Xa and factor IXa are inhibited by AT III and endogenous heparin probably enhances their inactivation. However, phospholipid-bound factor Xa in the presence of factor Va (Marciniak, 1973) and phospholipid-bound factor IXa (Varadi and Elödi, 1982) are relatively protected from inhibition. Platelet-bound factor Xa is completely protected from AT III, even in the presence of heparin (Miletich et al, 1978). Thus, specific cell surface sites modulate the inhibition of proteases in situ. Factor XIa is inhibited by several protease inhibitors, the most important being alpha 1-AT. beta-factor XIIa is inhibited mainly by C1-inhibitor and kallikrein by both C1-inhibitor and alpha 2M. No serine protease inhibitor for factor VIIa is as yet known. However, after initial rapid activation by factor Xa, factor VIIa is subsequently proteolytically inactivated by factor Xa, resulting in a transient burst of factor Xa generation by factor VIIa (Morrison and Jesty, 1984). This proteolytic regulation of factor VIIa by factor Xa dampens factor IX or factor X activation via tissue factor-factor VIIa by feedback proteolytic inhibition and this may constitute a major regulatory mechanism for factor VIIa.(ABSTRACT TRUNCATED AT 400 WORDS)
现在让我们简要总结一些主要的已知调节机制,其中大部分已经讨论过。凝血系统的一个普遍调节特征由辅助因子高分子量激肽原、组织因子、因子V(a)、因子VIII:C(a)、蛋白S和血栓调节蛋白提供。组织因子和血栓调节蛋白作为细胞膜成分,以及其他辅助因子,由于它们对某些表面位点的亲和力,使凝血反应定位,从而在凝血系统被触发时避免全身性血管内血栓形成。凝血酶激活因子V和VIII:C,而活化蛋白C使因子Va和VIII:Ca失活。凝血酶受抗凝血酶III、α2巨球蛋白以及可能的肝素辅因子II调节,由此内皮细胞结合的类肝素分子增强凝血酶的中和作用。此外,凝血酶与血栓调节蛋白的结合至少在兔血栓调节蛋白的情况下会消除其凝血活性。凝血酶能够从凝血酶原切割出PT片段1,从而产生缺乏γ-羧基谷氨酸区域且不与磷脂结合的凝血酶原1。然而,关于凝血酶可能通过这种负反馈调节自身形成的假说,可能必须被摒弃,因为在体外血液凝固后未发现相应片段(阿隆森等人,1977年)。因子Xa和因子IXa受抗凝血酶III抑制,内源性肝素可能增强它们的失活作用。然而,在因子Va存在下磷脂结合的因子Xa(马尔西尼亚克,1973年)和磷脂结合的因子IXa(瓦拉迪和埃洛迪,1982年)相对受到保护而免受抑制。血小板结合的因子Xa即使在有肝素存在的情况下也完全受到抗凝血酶III的保护(米莱蒂奇等人,1978年)。因此,特定的细胞表面位点原位调节蛋白酶的抑制作用。因子XIa受几种蛋白酶抑制剂抑制,其中最重要的是α1-抗胰蛋白酶。β-因子XIIa主要受C1抑制剂抑制,而激肽释放酶受C1抑制剂和α2巨球蛋白两者抑制。目前尚未发现针对因子VIIa的丝氨酸蛋白酶抑制剂。然而,在被因子Xa初始快速激活后,因子VIIa随后被因子Xa蛋白水解失活,导致因子VIIa短暂爆发性产生因子Xa(莫里森和杰斯蒂,1984年)。因子Xa对因子VIIa的这种蛋白水解调节通过反馈性蛋白水解抑制减弱了经由组织因子-因子VIIa对因子IX或因子X的激活,这可能构成因子VIIa的一种主要调节机制。(摘要截短至400字)